Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone734-887-3903
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees76
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Esperion Therapeutics (NASDAQ:ESPR) Frequently Asked Questions
What is Esperion Therapeutics' stock symbol?
Esperion Therapeutics trades on the NASDAQ under the ticker symbol "ESPR."
How were Esperion Therapeutics' earnings last quarter?
Esperion Therapeutics Inc (NASDAQ:ESPR) announced its earnings results on Thursday, August, 8th. The biopharmaceutical company reported ($2.01) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.86) by $0.15. The biopharmaceutical company earned $0.98 million during the quarter, compared to analyst estimates of $1.05 million. The company's quarterly revenue was up 9720.0% on a year-over-year basis. During the same quarter in the previous year, the business earned ($1.71) earnings per share. View Esperion Therapeutics' Earnings History.
When is Esperion Therapeutics' next earnings date?
What price target have analysts set for ESPR?
11 Wall Street analysts have issued 12-month price targets for Esperion Therapeutics' shares. Their predictions range from $47.00 to $114.00. On average, they expect Esperion Therapeutics' stock price to reach $76.30 in the next year. This suggests a possible upside of 98.6% from the stock's current price. View Analyst Price Targets for Esperion Therapeutics.
What is the consensus analysts' recommendation for Esperion Therapeutics?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Esperion Therapeutics in the last year. There are currently 1 sell rating, 3 hold ratings, 6 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Esperion Therapeutics.
What are Wall Street analysts saying about Esperion Therapeutics stock?
Here are some recent quotes from research analysts about Esperion Therapeutics stock:
- 1. Northland Securities analysts commented, "We remain highly optimistic that BA and its FDC combination will be approved on their respective PDUFA dates in late-February 2020. Further, we note that the Co. has bolstered its coffers with its recent $200MM revenue interest purchase agreement with Oberland Capital that added $125MM in 2Q19. Esperion reported 2Q results, with a lower- than-expected net loss of ($54.2MM), vs. our estimate of ($56.0MM). EPS tracked ($2.01) on lower shares outstanding of 27.0MM. RD spending totaled $42.8MM, slightly higher than our forecast of $40.0MM, which was offset by lower SG&A spending of $13.5MM, vs. our estimate of $16.0MM." (8/8/2019)
- 2. Chardan Capital analysts commented, "We find the relevant statistical analyses in the NEJM publications roughly consistent with those of our consulted biostatisticians and still see the following open issues as unresolved:." (3/14/2019)
- 3. According to Zacks Investment Research, "Esperion has no approved products in its portfolio. It focuses on developing new oral therapies for LDL-C lowering indications. The company’s pipeline products, bempedoic acid pill and bempedoic acid/Zetia combination pill achieved significant reduction in elevated bad cholesterol levels in hypercholesterolemia patients. The targeted area represents a significant opportunity. Esperion plans to file regulatory applications for both the candidates in the United States and Europe in the first half of 2019. However, Esperion neither has a marketed product nor a collaboration agreement to generate funds to support development and commercialization of its pipeline candidates. Esperion's share have outperformed the industry in past six months. Loss estimates have been stable ahead of Q4 earnings. Esperion has a mixed record of earnings surprise in the recent quarters." (2/8/2019)
Has Esperion Therapeutics been receiving favorable news coverage?
News coverage about ESPR stock has been trending negative recently, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Esperion Therapeutics earned a news impact score of -2.3 on InfoTrie's scale. They also gave news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for Esperion Therapeutics.
Who are some of Esperion Therapeutics' key competitors?
Some companies that are related to Esperion Therapeutics include Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of Esperion Therapeutics own?
Who are Esperion Therapeutics' key executives?
Esperion Therapeutics' management team includes the folowing people:
- Mr. Timothy M. Mayleben M.B.A., Pres, CEO & Director (Age 58)
- Dr. Narendra D. Lalwani, Exec. VP of R&D (Age 66)
- Mr. Richard B. Bartram, CFO & Corp. Sec. (Age 37)
- Mr. Alexander Duke Schwartz, Sr. Director of Investor Relations
- Ms. Marianne Andreach, Sr. VP
Who are Esperion Therapeutics' major shareholders?
Esperion Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (8.35%), BlackRock Inc. (7.37%), Wasatch Advisors Inc. (2.37%), Rhenman & Partners Asset Management AB (1.53%), Nuveen Asset Management LLC (1.42%) and Price T Rowe Associates Inc. MD (1.24%). Company insiders that own Esperion Therapeutics stock include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram, Roger S Newton, Target N V Biotech and Timothy M Mayleben. View Institutional Ownership Trends for Esperion Therapeutics.
Which major investors are selling Esperion Therapeutics stock?
ESPR stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Price T Rowe Associates Inc. MD, Rhenman & Partners Asset Management AB, A.R.T. Advisors LLC, Connor Clark & Lunn Investment Management Ltd., Creative Planning, Bank of America Corp DE and Tiverton Asset Management LLC. Company insiders that have sold Esperion Therapeutics company stock in the last year include Boxer Capital, Llc, Nicole Vitullo, Richard Bartram and Roger S Newton. View Insider Buying and Selling for Esperion Therapeutics.
Which major investors are buying Esperion Therapeutics stock?
ESPR stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Nuveen Asset Management LLC, Balyasny Asset Management LLC, Invesco Ltd., BlackRock Inc., ClariVest Asset Management LLC, JPMorgan Chase & Co. and Canada Pension Plan Investment Board. Company insiders that have bought Esperion Therapeutics stock in the last two years include Target N V Biotech and Timothy M Mayleben. View Insider Buying and Selling for Esperion Therapeutics.
How do I buy shares of Esperion Therapeutics?
Shares of ESPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Esperion Therapeutics' stock price today?
One share of ESPR stock can currently be purchased for approximately $38.41.
How big of a company is Esperion Therapeutics?
Esperion Therapeutics has a market capitalization of $1.04 billion. The biopharmaceutical company earns $-201,810,000.00 in net income (profit) each year or ($7.54) on an earnings per share basis. Esperion Therapeutics employs 76 workers across the globe.View Additional Information About Esperion Therapeutics.
What is Esperion Therapeutics' official website?
How can I contact Esperion Therapeutics?
Esperion Therapeutics' mailing address is 3891 RANCHERO DRIVE SUITE 150, ANN ARBOR MI, 48108. The biopharmaceutical company can be reached via phone at 734-887-3903 or via email at [email protected]
MarketBeat Community Rating for Esperion Therapeutics (NASDAQ ESPR)
MarketBeat's community ratings are surveys of what our community members think about Esperion Therapeutics and other stocks. Vote "Outperform" if you believe ESPR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ESPR will underperform the S&P 500 over the long term. You may vote once every thirty days.
